Keebeck Wealth Management acquired a new position in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,199 shares of the company’s stock, valued at approximately $635,000.
A number of other hedge funds and other institutional investors have also made changes to their positions in the company. BlackRock Inc. purchased a new position in shares of Medpace during the 2nd quarter valued at approximately $1,323,047,000. AQR Capital Management LLC boosted its holdings in Medpace by 31.6% during the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock worth $758,061,000 after buying an additional 324,293 shares in the last quarter. Wasatch Advisors LP grew its position in Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after buying an additional 116,354 shares during the period. Geode Capital Management LLC grew its position in Medpace by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after buying an additional 24,625 shares during the period. Finally, Invesco Ltd. grew its position in Medpace by 18.9% during the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after buying an additional 85,517 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.
Insiders Place Their Bets
In other news, Director Fred B. Davenport, Jr. sold 7,283 shares of the business’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the completion of the sale, the director owned 3,798 shares of the company’s stock, valued at $2,302,157.70. The trade was a 65.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Cornelius P. Mccarthy III sold 1,140 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $605.37, for a total transaction of $690,121.80. Following the transaction, the director owned 12,275 shares of the company’s stock, valued at approximately $7,430,916.75. This trade represents a 8.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 122,261 shares of company stock valued at $71,729,129. 20.50% of the stock is owned by company insiders.
Analyst Ratings Changes
View Our Latest Stock Report on Medpace
Medpace Stock Performance
Medpace stock opened at $620.75 on Friday. The company’s fifty day moving average price is $550.16 and its 200 day moving average price is $492.71. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90. The stock has a market capitalization of $17.33 billion, a P/E ratio of 36.39, a P/E/G ratio of 2.73 and a beta of 1.15.
Medpace (NASDAQ:MEDP – Get Free Report) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same period in the prior year, the business posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current year.
About Medpace
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Read More
- Five stocks we like better than Medpace
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
